MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
January 31, 2024Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio
January 31, 2024Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition
Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …
FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment
January 30, 2024Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma
Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …
Oxford Biomedica acquires ABL Europe for €15m
January 30, 2024Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …
EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59
January 29, 2024Medical Communications Arexvy, EMA, Infections and infestations, RSV
GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …
Vergent Bioscience shares phase 2 data for VGT-309
January 29, 2024Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer
Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …
MHRA approves Mounjaro for diabetes and weight management
January 26, 2024Medical Communications Diabetes, MHRA, Mounjaro, weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …
AbbVie invests $223m in Singapore manufacturing site
January 26, 2024Manufacturing and Production AbbVie, Pharmacy, Singapore, manufacturing
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more …
Haleon recalls cough syrups due to microbial contamination
January 25, 2024Medical Communications Haleon, Pharmacy, cough syrup, microbial contamination
The US Food and Drug Administration (FDA) has shared an announcement from Haleon detailing the voluntary recall of eight lots …
Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality
January 25, 2024Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab
Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …
Futura Medical appoints Roy Davis as non-executive director
January 25, 2024Business Services Futura Medical, Roy Davis, appointment, non-executive director
Futura Medical has announced the appointment of Roy Davis as non-executive director effective immediately. Roy has extensive commercial experience in …
Cellular Origins appoints Peter Crossley as chief operating officer
January 25, 2024Business Services Cellular Origins, Peter Crossley, appointment, chief operating officer
Cellular Origins, a TTP Company, has announced that it has appointed Peter Crossley as chief operating officer (COO). Peter brings …
BenevolentAI appoints Dr Joerg Moeller as CEO
January 25, 2024Business Services BenevolentAI, CEO, Dr Joerg Moeller, appointment
BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member …
Onward Therapeutics announces enrolment of phase 1 trial of bispecific antibody
January 24, 2024Research and Development Oncology, Onward Therapeutics, bispecific antibody, clinical trial
Onward Therapeutics has announced that it has begun enrolment for its phase 1 clinical trial of OT-A201, a novel bispecific …
InnoCare announces first patient dosed in zurletrectinib clinical trial in China
January 24, 2024Research and Development InnoCare, Oncology, clinical trial, zurletrectinib
InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second …
CN Bio and Altis Biosystems partner for development of in vitro model for ADME studies
January 23, 2024Research and Development ADME studies, Altis Biosystems, CN Bio, Pharmacy
CN Bio and Altis Biosystems have announced that they will enter a strategic partnership, through which Altis’ human RepliGut Planar-Jejunum …
Sanofi to acquire Inhibrx for approximately $1.7bn
January 23, 2024Business Services Inhibrx, Rare Diseases, Sanofi, acquisition
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following …
UKHSA warns of measles outbreak
January 22, 2024Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination
The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …
FDA approves Balversa for bladder cancer treatment
January 22, 2024Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer
Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
AstraZeneca’s Voydeya approved in Japan for PNH treatment
January 19, 2024Medical Communications AstraZeneca, Haematology, PNH, Voydeya
AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …
Latest content
FibroFind appoints Lee Borthwick as CEO
